Literature DB >> 26151313

Critical role of the NKG2D receptor for NK cell-mediated control and immune escape of B-cell lymphoma.

Lena Belting1, Nadine Hömberg1, Margarethe Przewoznik1, Christoph Brenner1, Tanja Riedel1, Andrew Flatley1, Bojan Polić2, Dirk H Busch3, Martin Röcken4, Ralph Mocikat1.   

Abstract

Little is known on the control of lymphomas by NK cells. Here, we study the role of the NK group 2D (NKG2D) receptor for the immunosurveillance of lymphoma. By using transplantable tumors as well as a λ-myc-transgenic model of endogenously arising lymphoma and NKG2D-deficient mice, we show that NK cells eliminate tumor cells in vivo after receiving two signals. One step involved the activation of NK cells giving rise to IFN-γ expression, which was effected by MHCI(low) tumor cells or DCs. However, this was necessary but not sufficient to mediate cytotoxicity. Triggering cytotoxicity additionally required a second step, which could be mediated by engagement of the NKG2D receptor. Thus, NKG2D-deficient NK cells could become activated in vivo, but they were not able to reject transplanted lymphomas or to degranulate in animals bearing autochthonous lymphomas. Tumor growth in NKG2D-deficient λ-myc-transgenic mice was significantly accelerated compared to NKG2D-competent animals. Whereas the latter developed tumors that lost expression of NKG2D ligands (NKG2D-L) in late disease stages, this did not occur in NKG2D-deficient mice. This indicates that NK cells and the NKG2D receptor play a role for control of lymphomas and that selection for NKG2D-L loss mutants provides a mechanism of tumor escape.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Endogenous B-cell lymphoma; NK-cell activation; NKG2D ligands; Tumor escape; λ-myc mouse

Mesh:

Substances:

Year:  2015        PMID: 26151313     DOI: 10.1002/eji.201445375

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

1.  CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma.

Authors:  Carolina Cubillos-Zapata; Raúl Cordoba; José Avendaño-Ortiz; Cristina Arribas-Jiménez; Enrique Hernández-Jiménez; Víctor Toledano; Teresa Villaescusa; Víctor Moreno; Eduardo López-Collazo
Journal:  Oncoimmunology       Date:  2016-09-16       Impact factor: 8.110

Review 2.  Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.

Authors:  M Pizzi; M Boi; F Bertoni; G Inghirami
Journal:  Leukemia       Date:  2016-06-08       Impact factor: 11.528

3.  TriKEs and BiKEs join CARs on the cancer immunotherapy highway.

Authors:  Szun Szun Tay; Hernan Carol; Maté Biro
Journal:  Hum Vaccin Immunother       Date:  2016-06-20       Impact factor: 3.452

4.  Chronic In Vivo Interaction of Dendritic Cells Expressing the Ligand Rae-1ε with NK Cells Impacts NKG2D Expression and Function.

Authors:  Maelig G Morvan; Marine Champsaur; Boris Reizis; Lewis L Lanier
Journal:  Immunohorizons       Date:  2017-05-01

5.  CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells.

Authors:  M Sauer; M Schuldner; N Hoffmann; A Cetintas; K S Reiners; O Shatnyeva; M Hallek; H P Hansen; S Gasser; E P von Strandmann
Journal:  Oncogene       Date:  2016-08-01       Impact factor: 9.867

6.  MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies.

Authors:  Srividya Swaminathan; Aida S Hansen; Line D Heftdal; Renumathy Dhanasekaran; Anja Deutzmann; Wadie D M Fernandez; Daniel F Liefwalker; Crista Horton; Adriane Mosley; Mariola Liebersbach; Holden T Maecker; Dean W Felsher
Journal:  Nat Commun       Date:  2020-06-05       Impact factor: 14.919

7.  Downregulation of MCT4 for lactate exchange promotes the cytotoxicity of NK cells in breast carcinoma.

Authors:  Yaping Long; Zihe Gao; Xiao Hu; Feng Xiang; Zhaozhen Wu; Jiahui Zhang; Xiao Han; Liyong Yin; Junfang Qin; Lan Lan; Fuzai Yin; Yue Wang
Journal:  Cancer Med       Date:  2018-07-26       Impact factor: 4.452

8.  Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A (CD161) interaction.

Authors:  Stephen O Mathew; Pankaj Chaudhary; Sheila B Powers; Jamboor K Vishwanatha; Porunelloor A Mathew
Journal:  Oncotarget       Date:  2016-10-18

Review 9.  Invariant Natural Killer T Cells in Immune Regulation of Blood Cancers: Harnessing Their Potential in Immunotherapies.

Authors:  Pui Yeng Lam; Michael D Nissen; Stephen R Mattarollo
Journal:  Front Immunol       Date:  2017-10-23       Impact factor: 7.561

Review 10.  Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma.

Authors:  Clifford M Csizmar; Stephen M Ansell
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.